Zealand Pharma - Interim report for the first half of 2018
(WorldNews Denmark)

Company announcement - No. 20 / 2018 Zealand Pharma - Interim report for the first half of 2018 Copenhagen, August 16, 2018 - Zealand Pharma A/S (`Zealand`) (Company reg. No. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery, design and development of innovative peptide-based medicines, today announced its financial results for the first half 2018. `In this past quarter we took important steps towards Phase 3 initiation with both glepaglutide for short bowel syndrome and dasiglucagon for congenital hyperinsulinism, our two leading rare disease programs. We also received positive feedback from the regulatory authorities and have committed more clinical study...